• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Akoya BioSciences Inc.

    4/23/24 6:04:57 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AKYA alert in real time by email
    DEFA14A 1 tm242865d2_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant x

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material under §240.14a-12

     

    Akoya Biosciences, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required.
       
    ¨ Fee paid previously with preliminary materials.
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

    GRAPHIC

    Your Vote Counts! AKOYA BIOSCIENCES, INC. 100 CAMPUS DRIVE, 6TH FLOOR MARLBOROUGH, MA 01752 ATTN: CORPORATE SECRETARY AKOYA BIOSCIENCES, INC. 2024 Annual Meeting Vote by June 3, 2024 11:59 PM ET Vote in Person at the Meeting* June 4, 2024 11:00 A.M., Eastern Time 500 Donald Lynch Boulevard Marlborough, MA 01752 *Please check the proxy materials for any special requirements for meeting attendance. You will need to request a ballot if you wish to vote these shares at the meeting. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V36628-P07034 You invested in AKOYA BIOSCIENCES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 4, 2024. Get informed before you vote We encourage you to access and review the proxy materials before voting. View the Notice and Proxy Statement and Form 10-K online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting prior to May 21, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming 2024 annual meeting of stockholders. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V36629-P07034 Voting Items Board Recommends 1. To elect three directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders; For Nominees: 01) Scott Mendel 02) Thomas P. Schnettler 03) Robert Shepler 2. To consider and vote upon the ratification of the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof will be voted on by the proxy holders in their discretion.

    Get the next $AKYA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKYA

    DatePrice TargetRatingAnalyst
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    8/6/2024Overweight → Equal-Weight
    Morgan Stanley
    8/6/2024Buy → Neutral
    BTIG Research
    8/6/2024Overweight → Neutral
    JP Morgan
    6/21/2024$7.50Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    7/5/2023$18.00Overweight
    JP Morgan
    2/2/2023$14.00Buy
    UBS
    More analyst ratings

    $AKYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Akoya Biosciences downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously

    11/15/24 8:33:16 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences downgraded by Morgan Stanley

    Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight

    8/6/24 12:17:30 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences downgraded by BTIG Research

    BTIG Research downgraded Akoya Biosciences from Buy to Neutral

    8/6/24 6:28:51 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

    RINCON, Puerto Rico, May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ:AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya. On May 20, 20

    5/23/25 2:21:00 PM ET
    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences Reports First Quarter 2025 Financial Results

    MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

    5/12/25 4:05:00 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

    It is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction Believes Quanterix's Maneuvers Further Demonstrate the Need for New Directors with Real Credibility and Accountability to Shareholders – And Will Press on With Nominations of Three Highly Qualified Board Candidates Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the "Amended Merger Agreement") relat

    4/30/25 8:00:00 AM ET
    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    SEC Filings

    View All

    SEC Form 15-12G filed by Akoya BioSciences Inc.

    15-12G - Akoya Biosciences, Inc. (0001711933) (Filer)

    7/18/25 9:25:03 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form EFFECT filed by Akoya BioSciences Inc.

    EFFECT - Akoya Biosciences, Inc. (0001711933) (Filer)

    7/14/25 12:15:03 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form S-8 POS filed by Akoya BioSciences Inc.

    S-8 POS - Akoya Biosciences, Inc. (0001711933) (Filer)

    7/8/25 1:06:41 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mendel Scott disposed of 28,500 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

    7/10/25 8:41:09 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Business Officer Ramachandran Niro Ph.D acquired 62,566 shares, covered exercise/tax liability with 42,148 shares and disposed of 282,555 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

    7/10/25 8:40:45 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Mckelligon Brian disposed of 947,688 shares, acquired 724,428 shares and covered exercise/tax liability with 196,866 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

    7/10/25 8:40:22 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    Financials

    Live finance-specific insights

    View All

    Akoya Biosciences Reports First Quarter 2025 Financial Results

    MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

    5/12/25 4:05:00 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

    MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i

    3/17/25 4:00:00 PM ET
    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

    Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ

    1/10/25 7:00:00 AM ET
    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    Leadership Updates

    Live Leadership Updates

    View All

    Akoya Biosciences Announces Leadership Transition

    Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ

    3/20/23 4:00:00 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel

    MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen

    2/28/23 8:00:00 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

    MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the

    4/19/22 8:05:00 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Akoya BioSciences Inc.

    SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

    11/4/24 7:39:24 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Akoya BioSciences Inc.

    SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)

    8/28/24 10:45:17 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Akoya BioSciences Inc. (Amendment)

    SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

    2/14/24 4:09:03 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials